Methyltestosterone [horm, phsu, strd]
Administration [ocac]
Plasma viscosity [lbpr]
postmenopausal [tmco]
Women [popg]
coronary heart disease [dsyn]
Leading [tmco]
Mortality [qnco]
Women [popg]
increases [ftcn]
Menopause [phsf]
Suggest [idcn]
Estrogen [horm, phsu, strd]
Menopause [phsf]
Androgen level [lbpr]
symptoms [ftcn]
Decreased Libido [sosy]
sexual dysfunction [dsyn]
Recently [tmco]
Interest [menp]
treatment [ftcn]
postmenopausal [tmco]
Women [popg]
Androgens [horm, phsu]
Available [ftcn]
Plasma viscosity [lbpr]
fibrinogen levels [lbpr]
postmenopausal [tmco]
Women [popg]
Combined therapy [topp]
Estrogen [horm, phsu, strd]
Androgen [horm, phsu]
Methods [inpr]
Conduct [inbe]
randomized [resa]
Double-Blind Study [resa]
Parallel [qlco]
Group [idcn]
Evaluate [ftcn]
effects [qlco]
Methyltestosterone [horm, phsu, strd]
Supplementation [topp]
Plasma viscosity [lbpr]
fibrinogen levels [lbpr]
postmenopausal [tmco]
Women [popg]
Estrogen Replacement Therapy [topp]
ERT [topp]
months [tmco]
Women [popg]
Old [tmco]
Menopausal [phsf]
Natural [ftcn]
Surgical [hlca]
months [tmco]
Study [mnob]
participants [popg]
randomized [resa]
Estrogen [horm, phsu, strd]
Group [idcn]
Take [hlca]
mg% [qnco]
Esterified estrogen [horm, phsu, strd]
Group [idcn]
Estrogen [horm, phsu, strd]
Plus [qlco]
Methyltestosterone [horm, phsu, strd]
mg% [qnco]
Esterified estrogen [horm, phsu, strd]
2 5 [qnco]
mg% [qnco]
Methyltestosterone [horm, phsu, strd]
Group [idcn]
EA [orch, phsu]
Group [idcn]
Progesterone [horm, phsu, strd]
Administered [ftcn]
Study [mnob]
Women [popg]
Intact [qlco]
Uteri [bpoc]
GIVEN [cnce]
Medroxyprogesterone [horm, phsu, strd]
mg% [qnco]
Daily [tmco]
days [tmco]
Completion [qlco]
Study [mnob]
weeks [tmco]
treatment [ftcn]
Group [idcn]
Serum estradiol level [lbpr]
baseline [bodm]
Levels [qlco]
total estrogen [horm, strd]
Group [idcn]
Compared [acty]
EA [orch, phsu]
Group [idcn]
P NOS [aapp, imft]
Decrease [qlco]
Levels [qlco]
EA [orch, phsu]
Group [idcn]
P NOS [aapp, imft]
Total testosterone [horm, phsu, strd]
Testosterone, Free [lbpr]
EA [orch, phsu]
Group [idcn]
P NOS [aapp, imft]
End [spco]
Study [mnob]
Decrease [qlco]
Plasma viscosity [lbpr]
EA [orch, phsu]
Group [idcn]
P NOS [aapp, imft]
fibrinogen levels [lbpr]
Increased [qnco]
Group [idcn]
Reaching [orgf]
EA [orch, phsu]
Group [idcn]
P NOS [aapp, imft]
Baseline weight [orga]
Body Mass Index [diap]
Duration [tmco]
Menopausal Status [clna]
IMPACT [gngm]
Plasma viscosity [lbpr]
Fibrinogen [aapp, bacs, phsu]
Women [popg]
EA [orch, phsu]
Group [idcn]
reductions [npop]
Total Cholesterol [lbpr]
P NOS [aapp, imft]
High density lipoprotein [aapp, bacs, lipd]
P NOS [aapp, imft]
Triglyceride level [lbtr]
P NOS [aapp, imft]
Parameters [fndg]
Group [idcn]
thi [euka]
Study, Prospective [resa]
treatment [ftcn]
postmenopausal [tmco]
Women [popg]
Estrogen [horm, phsu, strd]
Low dose [qnco]
Oral [spco]
Methyltestosterone [horm, phsu, strd]
reduction [npop]
Plasma viscosity [lbpr]
lowering [spco]
Plasma viscosity [lbpr]
fibrinogen levels [lbpr]
lowering [spco]
Lipoproteins [aapp, bacs]
Triglyceride level [lbtr]
Responsible [fndg]
Benefit [qnco]
Combination [qlco]
Regimen [topp]
side effects [ftcn]
Based [ftcn]
feel [menp]
Confident [inbe]
recommend [idcn]
Low dose [qnco]
Androgens [horm, phsu]
postmenopausal [tmco]
Women [popg]
History [ocdi]
sexual dysfunction [dsyn]
Decreased Libido [sosy]
